Best Cell Therapy CDMOs in Asia

← All Cell Therapy CDMOs Best Clean FDA History Commercial Scale

Region: USA Europe Asia

CDMOs tracked

Fully scored

With FDA records

FDA inspections

EMA/MHRA GMP certs

Warning letters

For Asia-manufactured cell therapy programs, WuXi Biologics, Minaris Advanced Therapies, and AGC Biologics lead CDMO Signal's ranking of cell therapy CDMOs with confirmed Asian manufacturing sites. Filtered from the global directory of 64 scored cell therapy CDMOs to 15 with Asia-Pacific facility presence. Asian CDMOs cover a range of regulatory jurisdictions — PMDA (Japan), NMPA (China), MFDS (South Korea), CDSCO (India) — each with distinct requirements. For sponsors supplying US and EU markets, cross-jurisdictional regulatory posture (FDA and EMA/MHRA inspection history on Asian facilities) is typically the qualifying signal. Rankings update as new inspection and certificate data enters the platform. Full methodology at cdmosignal.com/methodology.

Cell therapy CDMOs manufacture living products — CAR-T, TCR, NK, and stem-cell therapies — where the process is the product. Autologous programs add patient-scheduling and chain-of-identity demands that allogeneic, batch-based programs avoid.

The right cell therapy CDMO depends on autologous vs allogeneic experience, vector sourcing, closed-system processing, and cold-chain logistics. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 2 NAI (no action), 7 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: Denmark (18), Germany (6), India (5), INDIA (5), United States (4).

Last updated 2026-07-23. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

#	CDMO	Signal Score	Quality	FDA · GMP	Capacity	Programs
1	WB2 WuXi Biologics Shanghai, CN · Wuxi, CN	83.7	100.0	0 insp · 4 GMP	—	0 programs
2	MN Minaris Advanced Therapies Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP	83.5	100.0	1 insp · 6 GMP	Limited	0 programs
3	AG AGC Biologics Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP	80.6	99.9	2 insp · 23 GMP	Available	2 programs
4	SG Syngene International Bengaluru, India	79.7	95.9	2 insp · 0 GMP	—	0 programs
5	GS GenScript ProBio Piscataway, NJ · Nanjing, CN	79.5	100.0	—	Constrained	0 programs
6	BC Biocon Biologics Bangalore, India	77.1	96.1	4 insp · 1 GMP	—	0 programs
7	IP Intas Pharmaceuticals Ahmedabad, India	76.8	100.0	0 insp · 5 GMP	—	0 programs
8	HG Hitachi Global Life Solutions (CGT) Yokohama, Japan	63.0	—	—	—	0 programs
9	SM Sumitomo Chemical Advanced Medical Tokyo, JP	63.0	—	—	—	0 programs
10	EA Esco Aster Singapore, SG	63.0	—	—	—	0 programs
11	Minaris (WuXi Advanced Therapies) Philadelphia, PA / Yokohama, Japan	60.5	—	—	—	0 programs
12	CTP Cell Therapies Pty Ltd Melbourne, Australia	59.0	—	—	—	0 programs
13	SS Singota Solutions Bloomington, IN	59.0	—	—	—	0 programs
14	GC Green Cross Cell Yongin, KR	56.5	—	—	—	0 programs
15	CH CHA Medical & Bio Group Seongnam, KR	56.5	—	—	—	0 programs
—	Altruist Biologics Suzhou, China	Profiled	—	—	Available	0 programs
—	Kemwell Biopharma Bengaluru, India	Profiled	—	—	—	0 programs
—	Kemwell Biopharma, Bangalore Bengaluru, India	Profiled	—	—	—	0 programs
—	Magellan Stem Cells Sydney, Australia	Profiled	—	—	—	0 programs

How we score CDMOs →

What to evaluate in a Cell Therapy CDMO

Autologous vs allogeneic

Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model.

Vector & raw materials

Most cell therapies need a viral vector. Confirm whether the CDMO makes vector in-house or coordinates an external supplier, and how that affects timelines.

Closed-system & cleanrooms

Closed, automated processing reduces contamination risk and labor. Ask about cleanroom grade, automation platforms, and parallel-suite capacity.

Cold chain & logistics

Cryopreservation and chain-of-custody are critical for living cells. Evaluate the CDMO's cold-chain and apheresis-to-infusion logistics.

Regulatory landscape across PMDA (Japan), NMPA (China), MFDS (South Korea)

Asian biopharma manufacturing spans multiple national regulators. PMDA (Japan) is generally regarded as one of the most stringent in Asia, with GMP requirements broadly aligned with FDA and EMA. NMPA (China) has substantially strengthened its GMP framework over the past decade, and Chinese CDMOs increasingly hold FDA and EMA certifications alongside NMPA registration. MFDS (South Korea) certification is standard for Korean CDMOs. For sponsors supplying US or EU markets, the qualifying signal for an Asian CDMO is typically FDA and EMA inspection history on the specific facility — which the Signal Score's Quality Compliance pillar captures directly.

Which Asian CDMOs cover FDA (US) and EMA/MHRA (Europe) regulatory geographies?

Asian CDMOs with US FDA and European EMA/MHRA inspection history are qualified to supply global markets; those without cross-jurisdictional inspection posture are typically limited to their home-market regulatory scope. The Signal Score's Quality Compliance pillar includes FDA + EMA + MHRA data directly, so Asian CDMOs with cross-jurisdictional certification typically rank higher on this pillar than home-market-only competitors. Sponsors evaluating an Asian CDMO for a US or EU program should cross-check with the US region ranking and Europe region ranking — CDMOs appearing across regions have demonstrated multi-jurisdictional posture.

Recent US regulatory events affecting Asian CDMO selection (WuXi 1260H, BioSecure Act considerations)

Asian CDMOs — particularly Chinese-headquartered players — are subject to US regulatory events that affect sponsor risk assessment. The US Department of Defense's 1260H list (which added WuXi AppTec in June 2026) and the BioSecure Act (proposed federal legislation restricting federally-funded research and Medicare/Medicaid drug programs from working with named Chinese biotech companies) are both active considerations. CDMO Signal's platform does not encode US political risk into the Signal Score directly — the composite reflects regulatory quality, operations, financial stability, and capacity signals. Sponsors weighing an Asian CDMO for a US-supplying program should evaluate US regulatory risk separately as a distinct decision layer alongside the Signal Score-based capability assessment.

Cell Therapy CDMOs — Frequently Asked Questions

Who are the top Cell Therapy CDMOs?

By CDMO Signal's independent Signal Score, the top-ranked Cell Therapy CDMOs include WuXi Biologics, Minaris Advanced Therapies, AGC Biologics. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.

How many Cell Therapy CDMOs have FDA inspection records?

CDMO Signal tracks 4 Cell Therapy CDMOs with FDA inspection records and 39 EMA/MHRA GMP certificates across the group.

What should I look for in a cell therapy CDMO?

Match the CDMO to your model: autologous needs chain-of-identity and fast turnaround; allogeneic needs scalable batch processing. Confirm vector sourcing, closed-system processing, cold-chain logistics, and a clean FDA and EMA/MHRA record.

Do cell therapy CDMOs make their own viral vectors?

Some do in-house; others coordinate an external vector supplier. In-house vector can shorten timelines and simplify supply, but a strong external partner is common. Check each profile's modality coverage above.

Related modalities

Lentiviral Vector CDMOs CAR-T CDMOs Gene Editing CDMOs

Other Modalities

AAV CAR-T Lentiviral mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC